The average relative dose intensity of R‐CHOP is an independent factor determining favorable overall survival in diffuse large B‐cell lymphoma patients by Monika Długosz‐Danecka, Sebastian Szmit, Tomasz Ogórka, Aleksander B. Skotnicki, Wojciech Jurczak

Get full text

The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered by Peter Borchmann, Alexander Fosså, Monika Długosz-Danecka, Boris Böll, Markus Dietlein, Carsten Kobe, Helen Goergen, Andreas Engert

Get full text

Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies by Max Topp, Monika Dlugosz-Danecka, Aleksander B. Skotnicki, Galina Salogub, Andreas Viardot, Andreas K. Klein, Georg Hess, Christian S. Michel, Sebastian Grosicki, Alex Gural, Sylvia E. Schwarz, Kerstin Pietzko, Ulrike Gärtner, András Strassz, Leila Alland, Jiri Mayer

Get full text

Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study by Andrew M. Evens, Joseph M. Connors, Anas Younes, Stephen M. Ansell, Won Seog Kim, John Radford, Tatyana Feldman, Joseph Tuscano, Kerry J. Savage, Yasuhiro Oki, Andrew Grigg, Christopher Pocock, Monika Dlugosz-Danecka, Keenan Fenton, Andres Forero-Torres, Rachael Liu, Hina Jolin, Ashish Gautam, Andrea Gallamini

Get full text

Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prog... by Steven Le Gouill, Monika Długosz-Danecka, Simon Rule, Pier Luigi Zinzani, Andre Goy, Stephen D. Smith, Jeanette K. Doorduijn, Carlos Panizo, Bijal D. Shah, Andrew J. Davies, Richard Eek, Eric Jacobsen, Arnon P. Kater, Tadeusz Robak, Preetesh Jain, Roser Calvo, Lin Tao, Michael Wang

Get full text